Non-involuting congenital hemangioma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:141179D18.0
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Non-involuting congenital hemangioma (NICH) is a rare vascular tumor that is fully formed at birth and, unlike the more common infantile hemangiomas, does not undergo spontaneous regression or involution over time. NICH belongs to the group of congenital hemangiomas, which also includes rapidly involuting congenital hemangioma (RICH) and partially involuting congenital hemangioma (PICH). These lesions are distinct from infantile hemangiomas both clinically and histologically, and they are notably GLUT1-negative on immunohistochemistry, which helps differentiate them from infantile hemangiomas. NICH typically presents as a solitary, well-circumscribed, raised or flat vascular plaque or nodule on the skin. The lesion is often pink, violaceous, or bluish in color, sometimes with a pale rim or prominent overlying telangiectasias. It can occur anywhere on the body, including the head, trunk, and extremities. Because NICH persists indefinitely without regression, it may cause cosmetic concerns, and in some cases, it can be associated with local warmth, increased blood flow, or mild coagulopathy. The lesion primarily affects the skin and subcutaneous tissues, though deeper soft tissue involvement can occasionally occur. Treatment of NICH is primarily surgical excision when the lesion causes functional impairment, cosmetic disfigurement, or complications such as pain or ulceration. Unlike infantile hemangiomas, NICH does not respond to beta-blocker therapy (such as propranolol) or corticosteroids. In cases where surgery is not feasible or desired, observation and monitoring may be appropriate, as the lesions are generally benign. Embolization may be considered in select cases with significant arteriovenous shunting. Long-term prognosis is generally favorable, as malignant transformation has not been reported.

Also known as:

Clinical phenotype terms— hover any for plain English:

Midfrontal capillary hemangiomaHP:0007466Subcutaneous calcificationHP:0007618Perineal hemangiomaHP:0031449Prominent superficial veinsHP:0001015Hepatic hemangiomaHP:0031207Peripheral arteriovenous fistulaHP:0100784Visceral hemangiomaHP:0410266Tufted angiomaHP:0012329
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Non-involuting congenital hemangioma.

View clinical trials →

No actively recruiting trials found for Non-involuting congenital hemangioma at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Non-involuting congenital hemangioma community →

No specialists are currently listed for Non-involuting congenital hemangioma.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Non-involuting congenital hemangioma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Non-involuting congenital hemangiomaForum →

No community posts yet. Be the first to share your experience with Non-involuting congenital hemangioma.

Start the conversation →

Latest news about Non-involuting congenital hemangioma

No recent news articles for Non-involuting congenital hemangioma.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Non-involuting congenital hemangioma

What is Non-involuting congenital hemangioma?

Non-involuting congenital hemangioma (NICH) is a rare vascular tumor that is fully formed at birth and, unlike the more common infantile hemangiomas, does not undergo spontaneous regression or involution over time. NICH belongs to the group of congenital hemangiomas, which also includes rapidly involuting congenital hemangioma (RICH) and partially involuting congenital hemangioma (PICH). These lesions are distinct from infantile hemangiomas both clinically and histologically, and they are notably GLUT1-negative on immunohistochemistry, which helps differentiate them from infantile hemangiomas.

How is Non-involuting congenital hemangioma inherited?

Non-involuting congenital hemangioma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Non-involuting congenital hemangioma typically begin?

Typical onset of Non-involuting congenital hemangioma is neonatal. Age of onset can vary across affected individuals.